RxDoctor Payments Data

Melissa Wiesenhahn

Family · Cincinnati, OHNPI 1396199428

Payments from drug & device makers

$1,306in general payments, 2019–2025

Across 17 payments — averaging $76.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$572
  • Novo Nordisk$158
  • Phathom Pharmaceuticals, Inc.$126
  • Axsome Therapeutics, Inc.$125
  • Boehringer Ingelheim$123
  • AstraZeneca$118
  • plus $84 from 4 others

What the payments were for

  • Food & beverage$1,306100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,306 in reported general payments places this provider in the 75th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$25,718
Medicare patients
161
Services billed
843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$24,734
XareltoRivaroxaban17$23,649
EliquisApixaban22$17,185
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$14,815
Tiotropium Bromide11$4,219
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate20$3,762
Albuterol Sulfate HfaAlbuterol Sulfate95$2,613
Rosuvastatin Calcium153$2,094
Atorvastatin Calcium192$1,524
Omeprazole95$988
Lisinopril175$948
Levothyroxine Sodium96$895
Buspirone Hcl95$853
Fluticasone Propionate51$834
Celecoxib13$769

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$158$24,73423 claims
AbbVieSynthroid$572$54522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,812 family providers in Ohio.

Other family in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →